Stephan Moll
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Stephan Moll has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Christopher P. Garwacki
Department of Pathology, University of North Carolina School of Medicine, North Carolina
3 shared publications- Ming Yeong Lim
Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, UT
3 shared publications Amy Nopachai
Department of Medicine, University of North Carolina School of Medicine, North Carolina
2 shared publicationsBeth Waldron
From the Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of Medicine (S.M.), and the Hemophilia and Thrombosis Center, University of North Carolina (B.W.), Chapel Hill, NC.
2 shared publicationsCaron P. Misita
University of North Carolina Medical Center
2 shared publications- Christina Y. Lee
Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY
2 shared publications
Latest Publications
- 7 December 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (12) , 5235-5239
Livedoid vasculopathy in hemoglobinopathy-associated chronic leg ulcers
Chronic leg ulceration is a debilitating manifestation of hemoglobinopathies, and best management is uncertain. Livedoid vasculopathy (LV) is a cutaneous non-inflammatory thrombotic vasculopathy treated with anticoagulation that has been identified in hemoglobinopathy-associated chronic leg ulceration. However, most patients with hemoglobinopathy-associated ulcers do not undergo workup for secondary causes, and the prevalence and relevance of LV is unclear. Outcomes of secondary workup were examined retrospectively in this study. 108 patients with hemoglobinopathy-associated chronic leg ulcers were identified. 15% of patients underwent skin biopsy, and 97% of biopsies showed non-specific findings. Two patients had LV and neither responded to anticoagulants. Livedoid vasculopathy is a rare cause of ulceration in hemoglobin gene disorders and the benefit of anticoagulation in these cases is unclear.
- 7 December 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (12) , 5235-5239
Livedoid vasculopathy in hemoglobinopathy-associated chronic leg ulcers
Chronic leg ulceration is a debilitating manifestation of hemoglobinopathies, and best management is uncertain. Livedoid vasculopathy (LV) is a cutaneous non-inflammatory thrombotic vasculopathy treated with anticoagulation that has been identified in hemoglobinopathy-associated chronic leg ulceration. However, most patients with hemoglobinopathy-associated ulcers do not undergo workup for secondary causes, and the prevalence and relevance of LV is unclear. Outcomes of secondary workup were examined retrospectively in this study. 108 patients with hemoglobinopathy-associated chronic leg ulcers were identified. 15% of patients underwent skin biopsy, and 97% of biopsies showed non-specific findings. Two patients had LV and neither responded to anticoagulants. Livedoid vasculopathy is a rare cause of ulceration in hemoglobin gene disorders and the benefit of anticoagulation in these cases is unclear.
- 6 June 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (23) , 2351-2362
How I treat the co-occurrence of venous and arterial thromboembolism: anticoagulation, antiplatelet therapy, or both?
Arterial and venous thromboses are classically considered distinct disease states, with arterial thrombosis mediated predominantly by platelets and therefore, treated with antiplatelet therapy, and venous thrombosis mediated by the plasmatic coagulation system and treated with anticoagulation. However, co-occurrence of arterial and venous events is common, and there is increasing evidence of shared risk factors and pathophysiologic overlap. This presents a management challenge: does the patient with venous and arterial thrombosis, require anticoagulation, antiplatelet therapy, or both? Herein, we present a structured approach to the evaluation and management of patients with venous thrombosis who are also at risk for or have a history of an arterial thromboembolic event. We emphasize the importance of defining the indications for antithrombotic therapy, as well as the evaluation of factors that influence both thrombotic and bleeding risk, including disorder-specific and patient-specific factors, as well as the inherent risk balance of antithrombotic therapy regimens. We illustrate this approach in 4 cases, discussing the unique considerations and recent updates in the management of venous thrombosis, acute noncardioembolic ischemic stroke, coronary artery disease and acute myocardial infarction, and peripheral artery disease after revascularization.
- 6 June 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (23) , 2351-2362
How I treat the co-occurrence of venous and arterial thromboembolism: anticoagulation, antiplatelet therapy, or both?
Arterial and venous thromboses are classically considered distinct disease states, with arterial thrombosis mediated predominantly by platelets and therefore, treated with antiplatelet therapy, and venous thrombosis mediated by the plasmatic coagulation system and treated with anticoagulation. However, co-occurrence of arterial and venous events is common, and there is increasing evidence of shared risk factors and pathophysiologic overlap. This presents a management challenge: does the patient with venous and arterial thrombosis, require anticoagulation, antiplatelet therapy, or both? Herein, we present a structured approach to the evaluation and management of patients with venous thrombosis who are also at risk for or have a history of an arterial thromboembolic event. We emphasize the importance of defining the indications for antithrombotic therapy, as well as the evaluation of factors that influence both thrombotic and bleeding risk, including disorder-specific and patient-specific factors, as well as the inherent risk balance of antithrombotic therapy regimens. We illustrate this approach in 4 cases, discussing the unique considerations and recent updates in the management of venous thrombosis, acute noncardioembolic ischemic stroke, coronary artery disease and acute myocardial infarction, and peripheral artery disease after revascularization.
- Top Cited PapersOpen Access
- 28 November 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (22) , 7101-7138
American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing
Background: Hereditary and acquired thrombophilia are risk factors for venous thromboembolism (VTE). Whether testing helps guide management decisions is controversial. Objective: These evidence-based guidelines from the American Society of Hematology (ASH) intend to support decision making about thrombophilia testing. Methods: ASH formed a multidisciplinary guideline panel covering clinical and methodological expertise and minimizing bias from conflicts of interest. The McMaster University GRADE Centre provided logistical support, performed systematic reviews, and created evidence profiles and evidence-to-decision tables. The Grading of Recommendations Assessment, Development, and Evaluation approach (GRADE) was used. Recommendations were subject to public comment. Results: The panel agreed on 23 recommendations regarding thrombophilia testing and associated management. Nearly all recommendations are based on very low certainty in the evidence due to modeling assumptions. Conclusions: The panel issued a strong recommendation against testing the general population before starting combined oral contraceptives (COCs) and conditional recommendations for thrombophilia testing in the following scenarios: (a) patients with VTE associated with nonsurgical major transient or hormonal risk factors; (b) patients with cerebral or splanchnic venous thrombosis, in settings where anticoagulation would otherwise be discontinued; (c) individuals with a family history of antithrombin, protein C, or protein S deficiency when considering thromboprophylaxis for minor provoking risk factors and for guidance to avoid COCs/hormone replacement therapy; (d) pregnant women with a family history of high-risk thrombophilia types; and (e) patients with cancer at low or intermediate risk of thrombosis and with a family history of VTE. For all other questions, the panel provided conditional recommendations against testing for thrombophilia.
- 28 November 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (22) , 7101-7138
Top Cited PapersOpen AccessAmerican Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing
Background: Hereditary and acquired thrombophilia are risk factors for venous thromboembolism (VTE). Whether testing helps guide management decisions is controversial. Objective: These evidence-based guidelines from the American Society of Hematology (ASH) intend to support decision making about thrombophilia testing. Methods: ASH formed a multidisciplinary guideline panel covering clinical and methodological expertise and minimizing bias from conflicts of interest. The McMaster University GRADE Centre provided logistical support, performed systematic reviews, and created evidence profiles and evidence-to-decision tables. The Grading of Recommendations Assessment, Development, and Evaluation approach (GRADE) was used. Recommendations were subject to public comment. Results: The panel agreed on 23 recommendations regarding thrombophilia testing and associated management. Nearly all recommendations are based on very low certainty in the evidence due to modeling assumptions. Conclusions: The panel issued a strong recommendation against testing the general population before starting combined oral contraceptives (COCs) and conditional recommendations for thrombophilia testing in the following scenarios: (a) patients with VTE associated with nonsurgical major transient or hormonal risk factors; (b) patients with cerebral or splanchnic venous thrombosis, in settings where anticoagulation would otherwise be discontinued; (c) individuals with a family history of antithrombin, protein C, or protein S deficiency when considering thromboprophylaxis for minor provoking risk factors and for guidance to avoid COCs/hormone replacement therapy; (d) pregnant women with a family history of high-risk thrombophilia types; and (e) patients with cancer at low or intermediate risk of thrombosis and with a family history of VTE. For all other questions, the panel provided conditional recommendations against testing for thrombophilia.
- Open Access
- 30 October 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (21) , 6604-6607
Evaluating complement dysregulation in livedoid vasculopathy using a functional assay
- 30 October 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (21) , 6604-6607
Open AccessEvaluating complement dysregulation in livedoid vasculopathy using a functional assay
- Open Access
- 5 July 2023
- Published by Georg Thieme Verlag KG in TH Open
- Vol. 07 (03) , e191-e194
The Effect of Rituximab on Antiphospholipid Titers in Patients with Antiphospholipid Syndrome
Rituximab in patients with antiphospholipid syndrome (APS) is mostly used for treating noncriteria APS manifestations such as thrombocytopenia, and is not a first- or second-line treatment for management of thrombosis. However, at times rituximab is used empirically as adjunct treatment in patients with recurrent thrombosis occurring in spite of anticoagulant therapy (i.e., anticoagulation failure) when combinations of increased anticoagulation intensity, addition of antiplatelet therapy, and reduction of all thrombotic risk factors fail to prevent recurrent thrombosis.[1] [2] Knowledge of its effect on the naturally fluctuating antiphospholipid antibody (APLA) titers is, however, limited. We sought to determine the effect of rituximab on decreasing the magnitude and type of APLA in patients with thrombotic APS. K.Y. designed the study, collected the data, and was involved in the data analysis, and wrote the manuscript. S.M. designed the study and oversaw the manuscript, data collection, and analysis and manuscript writing. H.H. performed the statistical analysis; A.D. oversaw the statistical analysis. Received: 13 January 2023 Accepted: 21 April 2023 Article published online: 05 July 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 5 July 2023
- Published by Georg Thieme Verlag KG in TH Open
- Vol. 07 (03) , e191-e194
Open AccessThe Effect of Rituximab on Antiphospholipid Titers in Patients with Antiphospholipid Syndrome
Rituximab in patients with antiphospholipid syndrome (APS) is mostly used for treating noncriteria APS manifestations such as thrombocytopenia, and is not a first- or second-line treatment for management of thrombosis. However, at times rituximab is used empirically as adjunct treatment in patients with recurrent thrombosis occurring in spite of anticoagulant therapy (i.e., anticoagulation failure) when combinations of increased anticoagulation intensity, addition of antiplatelet therapy, and reduction of all thrombotic risk factors fail to prevent recurrent thrombosis.[1] [2] Knowledge of its effect on the naturally fluctuating antiphospholipid antibody (APLA) titers is, however, limited. We sought to determine the effect of rituximab on decreasing the magnitude and type of APLA in patients with thrombotic APS. K.Y. designed the study, collected the data, and was involved in the data analysis, and wrote the manuscript. S.M. designed the study and oversaw the manuscript, data collection, and analysis and manuscript writing. H.H. performed the statistical analysis; A.D. oversaw the statistical analysis. Received: 13 January 2023 Accepted: 21 April 2023 Article published online: 05 July 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 2 September 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (11) , 2703-2706
Hereditary angioedema is associated with an increased risk of venous thromboembolism
- 2 September 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (11) , 2703-2706
Hereditary angioedema is associated with an increased risk of venous thromboembolism
- Open Access
- 13 February 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (5) , 1158-1165
Risk of recurrence in women with venous thromboembolism related to estrogen‐containing contraceptives: Systematic review and meta‐analysis
- 13 February 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (5) , 1158-1165
Open AccessRisk of recurrence in women with venous thromboembolism related to estrogen‐containing contraceptives: Systematic review and meta‐analysis
- 26 December 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (1) , 263-264
Traditional risk factors and combined genetic markers of recurrent ischemic stroke in adults: Comment from Wilson et al.
- 26 December 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (1) , 263-264
Traditional risk factors and combined genetic markers of recurrent ischemic stroke in adults: Comment from Wilson et al.
- 24 September 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (13) , 1487-1498
How I treat unexplained arterial thrombosis
Most arterial thrombotic events have a clear atherosclerotic or cardioembolic etiology, but hematologists are frequently asked to assist in the diagnosis and management of a patient with a nonatherosclerotic and noncardioembolic arterial event, referred to here as an unexplained arterial thrombosis. Because there is an assorted list of factors that can precipitate an arterial event, we present a systematic diagnostic approach to ensure consideration of not only primary hypercoagulable disorders, but also pro-thrombotic medications or substances, vascular and anatomic abnormalities, and undiagnosed systemic disorders, such as malignancy and autoimmune diseases. We also review existing literature of the role of hypercoagulable disorders in arterial thrombosis and discuss our approach to thrombophilia workup in patients after an unexplained arterial event. We conclude with 3 representative cases to both illustrate the application of the outlined diagnostic schema and discuss common management considerations, specifically the selection of anticoagulation vs antiplatelet therapy for secondary prevention.
- 24 September 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (13) , 1487-1498
How I treat unexplained arterial thrombosis
Most arterial thrombotic events have a clear atherosclerotic or cardioembolic etiology, but hematologists are frequently asked to assist in the diagnosis and management of a patient with a nonatherosclerotic and noncardioembolic arterial event, referred to here as an unexplained arterial thrombosis. Because there is an assorted list of factors that can precipitate an arterial event, we present a systematic diagnostic approach to ensure consideration of not only primary hypercoagulable disorders, but also pro-thrombotic medications or substances, vascular and anatomic abnormalities, and undiagnosed systemic disorders, such as malignancy and autoimmune diseases. We also review existing literature of the role of hypercoagulable disorders in arterial thrombosis and discuss our approach to thrombophilia workup in patients after an unexplained arterial event. We conclude with 3 representative cases to both illustrate the application of the outlined diagnostic schema and discuss common management considerations, specifically the selection of anticoagulation vs antiplatelet therapy for secondary prevention.
- Open Access
- 24 December 2018
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 3 (2) , 152-155
Direct oral anticoagulants in extremely obese patients: OK to use?
- 24 December 2018
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 3 (2) , 152-155
Open AccessDirect oral anticoagulants in extremely obese patients: OK to use?